Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SPERO THERAPEUTICS, INC.

(SPRO)
  Rapport
Vertraagde tijd Nasdaq  -  22:00:00 02-02-2023
1.830 USD   -2.66%
01/02Spero Therapeutics, Inc. Benoemt Timothy Keutzer tot Chief Operating Officer, met ingang van 1 februari 2023
CI
2022Transcript : Spero Therapeutics, Inc., Q3 2022 Earnings Call, Nov 14, 2022
CI
2022Spero Therapeutics, Inc. rapporteert winstresultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2022
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
ETF's gepositioneerd op SPERO THERAPEUTICS, INC.ETF's en trackers met Trackinsight
ETF gewichtVariatie 5 dagenRatingGeografie
IShares Nasdaq US Biotechnology (D) - USD0.01%-1.14%VS
IShares Nasdaq US Biotechnology - USD0.01%-1.16%VS
IShares Biotechnology ETF - USD0.01%-0.06%-NC
Invesco Nasdaq Biotechnology ETF - USD0.01%-0.14%-VS



Copyright © 2009 Morningstar. All Rights Reserved. The information, data and opinions expressed (ďInformationĒ) and contained herein: (1) are proprietary to Morningstar and/or its content providers and are not intended to represent investment advice or recommendation to buy or sell any security; (2) may not be copied or distributed without express license to do so; and (3) are not warranted to be accurate, complete or timely. Morningstar reserve its rights to charge for access to these Ratings and/or Rating report. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this Rating, Rating Report or Information contained therein.
Grafiek SPERO THERAPEUTICS, INC.
Duur : Periode :
Spero Therapeutics, Inc. : Grafische technische analyse Spero Therapeutics, Inc. | MarketScreener
Grafiek op volledig scherm
Evolutie van de resultatenrekening
Consensus
Verkoop
Koop
Gemiddeld advies Kopen
Aantal analisten 4
Laatste slotkoers 1,83 $
Gemiddelde koersdoel 6,33 $
Spread / Gemiddelde doel 246%
Grafiek SPERO THERAPEUTICS, INC.
Duur : Periode :
Spero Therapeutics, Inc. : Grafische technische analyse Spero Therapeutics, Inc. | MarketScreener
Grafiek op volledig scherm
Sector en concurrentie
Verschil t.o.v. 1 jan (%)Kapitalisatie (M$)
SPERO THERAPEUTICS, INC.8.67%97
VERTEX PHARMACEUTICALS11.88%81 440
REGENERON PHARMACEUTICALS, INC.5.06%80 956
WUXI APPTEC CO., LTD.17.28%40 901
BIONTECH SE-4.77%34 764
BEIGENE, LTD.15.61%26 436